Evobrutinib (BioDeep_00000801684)
代谢物信息卡片
化学式: C25H27N5O2 (429.2164642)
中文名称: 依伏替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N
InChI: InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)
描述信息
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163774 - BTK-targeting Agent
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Holger Scheible, Martin Dyroff, Annick Seithel-Keuth, Eleanor Harrison-Moench, Nadra Mammasse, Andreas Port, Angelika Bachmann, Jennifer Dong, Jan Jaap van Lier, William Tracewell, David Mitchell. Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.
Clinical and translational science.
2021 11; 14(6):2420-2430. doi:
10.1111/cts.13108. [PMID: 34374206] - Andreas Becker, Emily C Martin, David Y Mitchell, Roland Grenningloh, Andrew T Bender, Julien Laurent, Harald Mackenzie, Andreas Johne. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Clinical and translational science.
2020 03; 13(2):325-336. doi:
10.1111/cts.12713. [PMID: 31654487] - Jie Yang, Haiyang Yu, Qingmeng Tang. Simultaneous determination of evobrutinib and its metabolite evobrutinib-diol in dog plasma by liquid chromatography combined with electrospray ionization tandem mass spectrometry.
Biomedical chromatography : BMC.
2019 Sep; 33(9):e4575. doi:
10.1002/bmc.4575. [PMID: 31069837] - Philipp Haselmayer, Montserrat Camps, Lesley Liu-Bujalski, Ngan Nguyen, Federica Morandi, Jared Head, Alison O'Mahony, Simone C Zimmerli, Lisa Bruns, Andrew T Bender, Patricia Schroeder, Roland Grenningloh. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Journal of immunology (Baltimore, Md. : 1950).
2019 05; 202(10):2888-2906. doi:
10.4049/jimmunol.1800583. [PMID: 30988116] - Viola Denzinger, Kristina Busygina, Janina Jamasbi, Isabell Pekrul, Michael Spannagl, Christian Weber, Reinhard Lorenz, Wolfgang Siess. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Thrombosis and haemostasis.
2019 Mar; 119(3):397-406. doi:
10.1055/s-0039-1677744. [PMID: 30685871] - James J Crawford, Adam R Johnson, Dinah L Misner, Lisa D Belmont, Georgette Castanedo, Regina Choy, Melis Coraggio, Liming Dong, Charles Eigenbrot, Rebecca Erickson, Nico Ghilardi, Jonathan Hau, Arna Katewa, Pawan Bir Kohli, Wendy Lee, Joseph W Lubach, Brent S McKenzie, Daniel F Ortwine, Leah Schutt, Suzanne Tay, BinQing Wei, Karin Reif, Lichuan Liu, Harvey Wong, Wendy B Young. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
Journal of medicinal chemistry.
2018 03; 61(6):2227-2245. doi:
10.1021/acs.jmedchem.7b01712. [PMID: 29457982]